ES2524369T3 - Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento - Google Patents

Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento Download PDF

Info

Publication number
ES2524369T3
ES2524369T3 ES10010211.0T ES10010211T ES2524369T3 ES 2524369 T3 ES2524369 T3 ES 2524369T3 ES 10010211 T ES10010211 T ES 10010211T ES 2524369 T3 ES2524369 T3 ES 2524369T3
Authority
ES
Spain
Prior art keywords
constipation
treatment
prostaglandin analogue
dosing unit
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10010211.0T
Other languages
English (en)
Spanish (es)
Inventor
Ryuji Ueno
Myra L. Patchen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2524369(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Application granted granted Critical
Publication of ES2524369T3 publication Critical patent/ES2524369T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
ES10010211.0T 2001-11-14 2002-11-14 Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento Expired - Lifetime ES2524369T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14
US331316P 2001-11-14

Publications (1)

Publication Number Publication Date
ES2524369T3 true ES2524369T3 (es) 2014-12-05

Family

ID=23293447

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10010211.0T Expired - Lifetime ES2524369T3 (es) 2001-11-14 2002-11-14 Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento
ES02780083T Expired - Lifetime ES2368729T3 (es) 2001-11-14 2002-11-14 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento del estreñimiento.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02780083T Expired - Lifetime ES2368729T3 (es) 2001-11-14 2002-11-14 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento del estreñimiento.

Country Status (14)

Country Link
US (3) US8097653B2 (https=)
EP (2) EP2298314B1 (https=)
JP (2) JP4852229B2 (https=)
AR (3) AR037524A1 (https=)
AT (1) ATE522218T1 (https=)
BR (1) BR0214075A (https=)
CA (1) CA2464420C (https=)
CY (1) CY1115856T1 (https=)
DK (2) DK2298314T3 (https=)
ES (2) ES2524369T3 (https=)
LU (1) LU92826I2 (https=)
PT (2) PT2298314E (https=)
TW (1) TWI331920B (https=)
WO (1) WO2003041716A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
NZ539582A (en) * 2002-10-23 2007-07-27 Sucampo Ag Prostaglandin compounds for the treatment of obesity
EP1575596B1 (en) * 2002-12-27 2016-06-22 Sucampo AG Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
RU2468800C2 (ru) * 2005-04-12 2012-12-10 Сукампо Аг Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний
MX2008009650A (es) * 2006-01-24 2008-11-06 R Tech Ueno Ltd Formulacion de capsula de gelatina suave.
JP5265369B2 (ja) * 2006-01-24 2013-08-14 株式会社アールテック・ウエノ 二環式化合物を含む医薬組成物およびその二環式化合物の安定化方法
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
AU2010295464B2 (en) * 2009-09-18 2015-11-26 Merck Sharp & Dohme Corp. Use of opioid receptor antagonist for gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
ES2051862T3 (es) * 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030346C (en) 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) * 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
DK0554794T3 (da) * 1992-02-04 1999-04-26 Eisai Co Ltd Aminobenzoesyrederivater
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
WO1997047595A1 (en) * 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
AU739343B2 (en) 1997-11-28 2001-10-11 Sucampo Ag Endothelin antagonist
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
BRPI0014869B8 (pt) * 1999-10-15 2021-05-25 Sucampo Ag prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
EP1267883B1 (en) 2000-04-06 2009-06-17 Sucampo AG Bile secretion promoting composition for liver transplantation containing a 15-keto-prostaglandin
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
ATE387204T1 (de) 2001-05-18 2008-03-15 Sucampo Ag Zusammensetzung mit induzierendem kathartischen effekt
EP1420794B1 (en) 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
EP1575596B1 (en) 2002-12-27 2016-06-22 Sucampo AG Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia

Also Published As

Publication number Publication date
DK1443938T3 (da) 2011-09-26
WO2003041716A1 (en) 2003-05-22
EP1443938B1 (en) 2011-08-31
ATE522218T1 (de) 2011-09-15
AR098997A2 (es) 2016-06-22
TWI331920B (en) 2010-10-21
EP2298314B1 (en) 2014-09-03
CA2464420A1 (en) 2003-05-22
CY1115856T1 (el) 2017-01-25
US8389542B2 (en) 2013-03-05
EP2298314A1 (en) 2011-03-23
BR0214075A (pt) 2004-09-28
TW200300091A (en) 2003-05-16
JP2011201905A (ja) 2011-10-13
CA2464420C (en) 2011-12-13
PT2298314E (pt) 2014-12-03
US8097653B2 (en) 2012-01-17
JP2005513014A (ja) 2005-05-12
US20130143958A1 (en) 2013-06-06
US20120088824A1 (en) 2012-04-12
US20030119898A1 (en) 2003-06-26
HK1155649A1 (en) 2012-05-25
DK2298314T3 (en) 2014-12-01
ES2368729T3 (es) 2011-11-21
AR037524A1 (es) 2004-11-17
LU92826I2 (fr) 2015-11-24
EP1443938A1 (en) 2004-08-11
AR117404A2 (es) 2021-08-04
PT1443938E (pt) 2011-09-27
JP4852229B2 (ja) 2012-01-11

Similar Documents

Publication Publication Date Title
ES2524369T3 (es) Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
AR004108A1 (es) Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
ES2176436T3 (es) Nueva forma de dosificacion farmaceutica oral.
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
NO20055880L (no) Memantin orale doseringsformer
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
ES2093735T3 (es) Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
DK0503440T3 (da) Sumatriptanholdige lægemidler
AR039335A1 (es) Tableta de carga de droga alta
MX9203444A (es) Medicamentos.
ES2114562T3 (es) Forma de dosificacion para distribucion retardada de farmacos.
AR029174A1 (es) Derivados de espirooxindol, proceso para su preparacion, formulacion farmaceutica, y utilizacion de los derivados en la manufactura de medicamentos
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
AR045161A1 (es) Derivados de quinazolina
CR9842A (es) Composiciones de celecoxib
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
ES2176106A1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
KR970025615A (ko) 암 전이 억제제